Nutriband INC 8-K filings

Nutriband Inc. has selected a commercial brand name for its abuse-deterrent fentanyl transdermal system and plans to submit it to regulatory agencies for approval.

Nutriband Inc. has terminated its agreement to sell subsidiary Pocono Pharmaceuticals, Inc. to Earth Vision Bio Inc. due to the buyer's failure to pay late fees.

Nutriband, Inc. announced shareholder approval of all proposals at its 2026 Annual Meeting, including the election of directors and an increase in authorized preferred stock.

Nutriband Inc. announced the sale of a 90% interest in its subsidiary Pocono Pharmaceutical for $5 million USD to EarthVision Bio, retaining a 10% stake in EarthVision Bio.

Nutriband Inc. announced successful feedback from the U.S. FDA on its AVERSA FENTANYL abuse-deterrent patch, paving the way for an Investigational New Drug (IND) filing.

Nutriband Inc. announced the exercise of stock options and warrants, generating over $5.3 million in proceeds and issuing 845,172 new shares between February and July 2025.

Nutriband Inc. has authorized and issued new Series A Convertible Preferred Stock via a stock dividend, contingent on future FDA approval for conversion to common shares.

Nutriband Inc. has amended its Articles of Incorporation to authorize a new series of convertible preferred stock and declared a dividend of these shares to existing common shareholders.

Nutriband Inc. announces a partnership with Charlotte FC to increase brand awareness, particularly for AI Tape manufactured in the Charlotte area.

Nutriband and Kindeva Drug Delivery strengthen their collaboration to develop Aversa Fentanyl, an abuse-deterrent transdermal patch, through a revised agreement involving shared development costs and milestone payments.

Nutriband Inc. has received a Notice of Allowance from the USPTO for its patent application covering Aversa abuse deterrent technology, potentially leading to the issuance of a U.S. patent.

Nutriband, Inc. held its 2025 Annual Meeting of Stockholders on January 23, 2025, and announced the results of the votes on director elections, auditor ratification, stock option plan approval, and executive compensation advisory votes.

Nutriband has extended its AVERSA abuse-deterrent transdermal technology patent to Macao and is targeting FDA approval for AVERSA Fentanyl in the first half of 2025.

Nutriband has received full patent issuance from the Chinese National Intellectual Property Administrant for its AVERSA abuse-deterrent transdermal technology.

Nutriband Inc. has announced a $1 million share buyback program and reaffirmed its timeline for submitting an NDA for its AVERSA Fentanyl product in early 2025.

Nutriband Inc. amended a debt conversion agreement to issue shares and warrants to TII Jet Services, LDA, in exchange for $300,000 of debt.

Nutriband Inc. converted $300,000 of debt into 76,230 shares of common stock at a price of $4.00 per share.

Nutriband Inc. has appointed Sergei Glinka, a seasoned commercial manager, to its Board of Directors effective May 15, 2024.

Nutriband Inc. has successfully completed an $8.4 million equity financing round with European investors, issuing units consisting of common stock and warrants.

Nutriband Inc. has amended its employee stock option plan, increasing the number of shares available and granting options to key executives and consultants.

Nutriband, Inc. held its 2023 Annual Meeting of Stockholders on January 21, 2024, where shareholders voted on the election of directors, ratification of the audit firm, and executive compensation matters.

Nutriband has entered into a commercial agreement with Kindeva Drug Delivery to develop and manufacture their Aversa abuse-deterrent fentanyl patch.